Subtype-Specific Tumour Immune Microenvironment in Risk of Recurrence of Ductal Carcinoma In Situ: Prognostic Value of HER2

• Published in: Biomedicines Vol. 10; no. 5; p. 1061
• Main Authors: Solek, Julia, Chrzanowski, Jedrzej, Cieslak, Adrianna, Zielinska, Aleksandra, Piasecka, Dominika, Braun, Marcin, Sadej, Rafal, Romanska, Hanna M
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 03.05.2022; MDPI
• Subjects: Biomarkers; Breast cancer; Breast carcinoma; DCIS; Epidermal growth factor; ErbB-2 protein; Estrogens; Evolution; HER2; Infiltration; Invasiveness; Lymphocytes; Metastases; Microenvironments; PD-1 protein; PD-L1 protein; recurrence; Review; Tumors; tumour immune microenvironment; recurrence; tumour immune microenvironment; HER2; DCIS
• ISSN: 2227-9059; 2227-9059
• DOI: 10.3390/biomedicines10051061

Increasing evidence suggests that the significance of the tumour immune microenvironment (TIME) for disease prognostication in invasive breast carcinoma is subtype-specific but equivalent studies in ductal carcinoma in situ (DCIS) are limited. The purpose of this paper is to review the existing data on immune cell composition in DCIS in relation to the clinicopathological features and molecular subtype of the lesion. We discuss the value of infiltration by various types of immune cells and the PD-1/PD-L1 axis as potential markers of the risk of recurrence. Analysis of the literature available in PubMed and Medline databases overwhelmingly supports an association between densities of infiltrating immune cells, traits of immune exhaustion, the foci of microinvasion, and overexpression of HER2. Moreover, in several studies, the density of immune infiltration was found to be predictive of local recurrence as either in situ or invasive cancer in HER2-positive or ER-negative DCIS. In light of the recently reported first randomized DCIS trial, relating recurrence risk with overexpression of HER2, we also include a closing paragraph compiling the latest mechanistic data on a functional link between HER2 and the density/composition of TIME in relation to its potential value in the prognostication of the risk of recurrence.